Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578368 | 0.88 | CNR2 (0.41) | TRPV1CNR2MEN1ALDH1A1MAPT | |
| SCHEMBL1725351 | 0.86 | TRPV1 (0.42) | TRPV1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1578462 | 0.86 | MEN1 (0.43) | TRPV1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1725911 | 0.86 | NAMPT (0.41) | TRPV1SMN1; SMN2 | |
| SCHEMBL1578543 | 0.86 | TRPV1 (0.41) | TRPV1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2174963 | 0.85 | TRPV1 (0.36) | TRPV1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2175852 | 0.85 | TRPV1 (0.36) | TRPV1MEN1ALDH1A1KMT2AJAK1 | |
| SCHEMBL1578587 | 0.85 | GRIN2B (0.39) | TRPV1 | |
| SCHEMBL1578182 | 0.84 | TRPV1 (0.42) | TRPV1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1578546 | 0.84 | TRPV1 (0.40) | TRPV1MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-11-15 | — | — | US | claimed |
| US-8247404-B2 | Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same | SANOFI (FR) | 2012-08-21 | — | — | US | claimed |
| WO-2011144835-A3 | TUBULAR PHOTOVOLTAIC DEVICE FOR PRODUCING ELECTRICAL ENERGY | THEROND PATRICK (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-2310383-B1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2011-11-30 | — | — | EP | claimed |
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| US-20170189522-A1 | PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2017-07-06 | — | — | US | disclosed |
| WO-2015181298-A1 | PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY | Technische Universität Dresden (DE) | 2015-12-03 | — | — | WO | disclosed |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-11-15 | — | — | US | disclosed |
| US-8247404-B2 | Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same | SANOFI (FR) | 2012-08-21 | — | — | US | disclosed |
| WO-2011144835-A3 | TUBULAR PHOTOVOLTAIC DEVICE FOR PRODUCING ELECTRICAL ENERGY | THEROND PATRICK (FR) | 2012-05-10 | — | — | WO | disclosed |
| EP-2310383-B1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2310383-A1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009150387-A1 | DERIVATIVES OF 2-OXO-ALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144122-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | TRPV1 940/4885CNR2 21/4885MEN1 2350/4885 |
| US-20120289518-A1 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | PKD2, OPRM1, DHFR | TRPV1 940/4885CNR2 21/4885MEN1 2350/4885 |
| US-20170189522-A1 | PHARMACEUTICAL COMBINATIONS FOR IMMUNOTHERAPY | TLR9, TLR7, TLR3 | TRPV1 268/4885CNR2 212/4885MEN1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.